TANDEM DIABETES CARE INC (TNDM)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Sales | 240,678 | 234,422 | 243,971 | 221,910 |
| Cost of sales | 114,823 | 116,015 | 119,318 | 109,116 |
| Gross profit | 125,855 | 118,407 | 124,653 | 112,794 |
| Selling, general and administrative | 109,596 | 113,853 | 99,639 | 94,242 |
| Research and development | 48,118 | 50,215 | 51,107 | 49,326 |
| Acquired in-process research and development expenses | - | 75,217 | - | - |
| Litigation settlement expense | 19,951 | - | - | - |
| Total operating expenses | 177,665 | 239,285 | 150,746 | 143,568 |
| Operating loss | -51,810 | -120,878 | -26,093 | -30,774 |
| Interest income and other, net | - | 4,193 | 5,344 | 2,824 |
| Interest expense | 1,905 | 1,862 | 1,865 | 1,793 |
| Loss from equity method investments | -3,375 | -3,542 | - | - |
| Loss on extinguishment of debt | - | - | - | - |
| Interest income and other income (expense), net | -632 | - | - | - |
| Total other income (expense), net | -5,912 | -1,211 | 3,479 | 1,031 |
| Loss before income taxes | -57,722 | -122,089 | -22,614 | -29,743 |
| Income tax expense (benefit) | -5,322 | 8,467 | 637 | 1,071 |
| Net loss | -52,400 | -130,556 | -23,251 | -30,814 |
| Foreign currency translation gains (losses) | 4,380 | 1,599 | 1,175 | 145 |
| Unrealized gain (loss) on short-term investments | -98 | - | - | - |
| Unrealized loss on cash flow hedges | -612 | - | - | - |
| Unrealized gain (loss) on short-term investments | - | 423 | 3,948 | -463 |
| Comprehensive loss | -48,730 | -128,534 | -18,128 | -31,132 |
| Net loss per share - basic (in dollars per share) | -0.78 | -1.97 | -0.35 | -0.47 |
| Net loss per share - diluted (in dollars per share) | -0.78 | -1.97 | -0.35 | -0.47 |
| Weighted average shares used to compute basic net loss per share (in shares) | 67,050,000 | 66,404,000 | 65,538,000 | 64,994,000 |
| Weighted average shares used to compute diluted net loss per share (in shares) | 67,050,000 | 66,404,000 | 65,538,000 | 64,994,000 |